Company profile
Reme-D, Inc.
Reme-D, Inc. is an Egypt-based molecular-diagnostics manufacturer that develops diagnostic kits for infectious, genetic and other diseases. The company manufactures molecular tests designed for use in settings with limited cold-chain and laboratory infrastructure, including tests for tuberculosis, human immunodeficiency virus, hepatitis and human papillomavirus. Reme-D sells to public and private laboratories, hospitals and research institutions. Its website lists nucleic-acid extraction, diagnostic and research-use tools, while recent funding coverage reports that it has commercialised 30 products and supplied more than 550,000 tests in Egypt, Kenya and Sudan.
- Sector
- Healthcare / Medical Supplies, Biotechnology
- Markets
- Sudan, Egypt, Kenya
- Founded
- 2023
- Ownership
- Private
- Stage
- Startup
- Capital raised
- $2.9m
- Employees
- 11-50
- Business model
- B2B Manufacturing, Transactional
Products and services
Nucleic Acid Extraction, Molecular Diagnostics, Research Use Tools, Hepatitis C Virus Detection PCR Kit, Human Immunodeficiency Virus PCR Testing, Tuberculosis PCR Testing & Human Papillomavirus Testing
Transactions
| Date | Transaction | Type | Value | Market |
|---|---|---|---|---|
| 24 Jul 2026 | Anara Impact Capital, Global Innovation Fund, and Africa Health Ventures invest USD 1.45 million in Reme-D | Venture Capital | $1.5m | Egypt |
| 20 Jul 2026 | Anara Impact Capital and partners invest USD 1.45 million in Reme-D's operations in Egypt | Venture Capital | $1.5m | Egypt |
Source: Partner Researchers.